"The US Food and Drug Administration (FDA) has approved an expanded indication for onabotulinum toxin A (Botox, Actavis) for the treatment of adults with upper limb spasticity, according to a company news release.
The expanded i"...
Sodium Lactate (sodium lactate injection in aviva) Injection, USP is primarily indicated, after dilution, as a source of bicarbonate for prevention or control of mild to moderate metabolic acidosis in patients with restricted oral intake whose oxidative processes are not seriously impaired. It is not intended nor effective for correcting severe acidotic states which require immediate restoration of plasma bicarbonate levels. Sodium lactate (sodium lactate injection in aviva) has no advantage over sodium bicarbonate and may be detrimental in the management of lactic acidosis.
DOSAGE AND ADMINISTRATION
Sodium Lactate (sodium lactate injection in aviva) Injection, 50 mEq (5 mEq/ mL), is administered intravenously only after addition to a larger volume of fluid.The amount of sodium ion and lactate ion to be added to larger volume intravenous fluids should be determined in accordance with the electrolyte requirements of each individual patient.
All or part of the contents of one (50 mEq in 10 mL) or more vial containers may be added to other intravenous solutions to provide any desired number of milliequivalents of lactate anion (with the same number of milliequiva-lents of Na+). The contents of one container (50 mEq in 10 mL) added to 290 mL of a nonelectrolyte solution or of Sterile Water for Injection will provide 300 mL of an approximately isotonic (1/6 molar) concentration of sodium lactate (sodium lactate injection in aviva) (1.9%), containing 167 mEq/L each of Na+ and lactate anion.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
|Product No.||NDC No.|
|37510||63323-375-10||Sodium Lactate Injection, USP, 50 mEq (5 mEq/mL) in a 10 mL flip-top single dose vial, in packages of 25.|
Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].
Abraxis Pharmaceutical Products, Schaumburg, IL 60173. Revised: July 2006. FDA rev date: 8/14/2001
Last reviewed on RxList: 1/16/2009
This monograph has been modified to include the generic and brand name in many instances.
Additional Sodium Lactate Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.